The Legal 500 > DLA Piper > Oslo, NORWAY > Lawyer profiles

DLA Piper

BRYGGEGATA 6, PO BOX 1364, VIKA, 0114 OSLO, NORWAY

Tel:: Work +47 24 13 15 00
Fax:: Fax +47 24 13 15 01

Email:

Web:: www.dlapiper.no

Aarhus, Abu Dhabi, Accra, Addis Ababa, Al-Khobar, Algiers and 123 more

Kaare Oftedal

Email:

Web:: www.dlapiper.com/en/norway/people/o/oftedal-kaare/

Profile
Lawyer Rankings

Work Department

Commercial, Corporate and M&A

Position

Country Managing Partner

Languages

Kaare Oftedal is an experienced M&A lawyer. Besides overall commercial legal advice in business contract negotiations, he assists clients in connection with corporate transactions and M&A, both national and cross-border, including investments, acquisitions, reorganization and equity transactions. He assists both Norwegian and foreign clients from a broad range of industries.

Kaare Oftedal has in-depth knowledge about Norwegian company legislation, and has extensive experience in establishment of businesses, joint-ventures and shareholders agreements, mergers and demergers, company restructuring, compliance and contract negotiation.

Oftedal also has experience in the private equity sector, including with the creation of - and investment in - investment funds, management and advisory structures, investment in portfolio companies, buying and selling of portfolio companies and other M&A in that regard.

Norway

Commercial, corporate and M&A

Within: Commercial, corporate and M&A

DLA Piper's practice has 'a hands-on and pragmatic approach' and includes managing partner Kaare Oftedal, who is 'effective, exceptionally service minded and confident enough to ask the extra questions other legal counsels might not dare', practice head Sveinung Mjaugedal, Fredrik Lykke and private equity expert Christian Fenner. The group assisted QuMei Home Furnishing Group and Huatai Zijin Investment with its public tender offer for Ekornes, and acted for Urbaser on its acquisition of RenoNorden. Stan Stewart joined from Baker McKenzie LLP.

[back to top]

Electricity and renewable energy

Within: Electricity and renewable energy

Led by Fredrik Lindblom, DLA Piper's practice is a key name for project finance work, with notable expertise in the onshore wind sector. In a recent highlight, Lindblom advised DekaBank Deutsche Girozentrale on the project financing of an onshore wind farm project in Northern Norway. Other key individuals include transactional specialist Kaare Oftedal and finance experts Dag Thomas Hansson and Erik Ramm.

[back to top]

Back to index

Search News and Articles

Legal Developments by:
DLA Piper LLP (US)

Sentencing guidelines for corporate manslaughter

In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company. 

- DLA Piper UK LLP

Legal Developments in Norway

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

Norway not included when short sale regulations in EU take effect 1 November 2012

From 1 November 2012 EU Regulation 236/2012 on short selling and certain aspects of credit default swaps will come into effect. Although the Regulation is within the scope of the EEA Agreement, Norway has not implemented the EU Regulation. Based on unofficial information from the Norwegian authorities, we expect the implementation process to be delayed until at least late 2013. Meanwhile, existing rules on short sale in Norway will continue to apply for transactions performed on the Norwegian market.

- Kluge Advokatfirma DA
Proposed ban on personal import of medicinal products ordered via Internet

The Ministry of Health and Care has recently issued a hearing letter proposing stringent restrictions on import of medicinal products for personal use. Among the actions proposed, is a general ban on the import of prescription drugs, and access for Customs to seize and destroy falsified or illegal medicinal products.

- Advokatfirmaet Grette DA
Increased transparency for applications for marketing authorisation

On 17th July 2012, the Norwegian Medicines Agency (NMA) announced a change in their practice regarding disclosure of information for applications of marketing authorisations for medicinal products.

- Advokatfirmaet Grette DA
New Patent Office Act to enter into effect on 1st January 2013

A new Act on the Patent Office and Industrial Property Rights Appeals Commission (the Patent Office Act) will be enacted and come into effect on 1st January 2013. The current Act on the Industrial Property Protection Board was enacted in 1910, and time for a complete reform had come.

- Advokatfirmaet Grette DA
Sunset clause for medicinal products in Norway

"Sunset clause" is a common term for the provision which could lead to the cessation of the validity of the marketing authorisation of a medicinal product.

- Advokatfirmaet Grette DA
New review on pension schemes

Questions on pensions have long had a large political focus in Norway, in connection with pension reforms such as obligatory occupational pension and changes in the National Insurance Scheme.

- Advokatfirmaet Grette DA
New provisions on competition clauses

In 2011 it was expected that new provisions for competition clauses, customer clauses and non-recruitment clauses would come into force. As early as June 2010, the Department of Employment sent a proposal on new provisions in the Working Environment Act for comments.

- Advokatfirmaet Grette DA
Norway implements the EU block exemption regulation for R&D agreements

Earlier this year, EU Commission Regulation No 1217/2010 was implemented in Norwegian law.

- Advokatfirmaet Grette DA
Hearing: Reimbursement of off-label use of medicinal products

In accordance with the provisions of the Act on Medicines and the appurtenant Regulation on Medicinal Products, pre-approved reimbursement for use of a medicinal product outside the approved indications of the marketing authorization is not allowed.

- Advokatfirmaet Grette DA
New review on pension schemes

Questions on pensions have long had a large political focus in Norway, in connection with pension reforms such as obligatory occupational pension and changes in the National Insurance Scheme.

- Advokatfirmaet Grette DA

Lawyer rankings